Last €17.01 EUR
Change Today +0.111 / 0.66%
Volume 0.0
0PT On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 9:35 AM 08/29/14 All times are local (Market data is delayed by at least 15 minutes).

prothena corp plc (0PT) Snapshot

Open
€16.92
Previous Close
€16.90
Day High
€17.01
Day Low
€16.92
52 Week High
03/20/14 - €36.00
52 Week Low
07/18/14 - €12.61
Market Cap
465.8M
Average Volume 10 Days
22.8
EPS TTM
--
Shares Outstanding
27.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PROTHENA CORP PLC (0PT)

Related News

No related news articles were found.

prothena corp plc (0PT) Related Businessweek News

No Related Businessweek News Found

prothena corp plc (0PT) Details

Prothena Corporation plc, a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of novel antibodies for the treatment of various diseases associated with protein misfolding or cell adhesion. Its product pipeline includes NEOD001, a product candidate in Phase 1 clinical trial to target AL and AA forms of amyloidosis; PRX002 for the treatment of Parkinson’s disease and related synucleinopathies; and PRX003 for the treatment of inflammatory disease and metastatic cancers. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein. Prothena Corporation plc was incorporated in 2012 and is headquartered in Dublin, Ireland.

39 Employees
Last Reported Date: 03/7/14
Founded in 2012

prothena corp plc (0PT) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $462.1K
Chief Financial Officer
Total Annual Compensation: $278.8K
Chief Scientific Officer and Head of Research...
Total Annual Compensation: $349.2K
Chief Business Officer
Total Annual Compensation: $265.3K
Compensation as of Fiscal Year 2013.

prothena corp plc (0PT) Key Developments

Prothena Corporation plc Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Provides Earnings Guidance for the Year 2014

Prothena Corporation plc reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company's total revenue was $15,121,000 compared to $167,000 a year ago. Income from operations was $1,569,000 compared to loss from operations of $11,192,000 a year ago. Income before income taxes was $1,586,000 compared to loss before income taxes of $11,178,000 a year ago. Net income was $1,290,000 compared to net loss of $11,302,000 a year ago. Net income per share attributable to holders of ordinary shares - diluted was $0.06 compared to loss of $0.64 a year ago. For the six months, the company's total revenue was $47,355,000 compared to $338,000 a year ago. Income from operations was $19,588,000 compared to loss from operations of $20,159,000 a year ago. Income before income taxes was $19,589,000 compared to loss before income taxes of $20,123,000 a year ago. Net income was $19,142,000 compared to net loss of $20,253,000 a year ago. Net income per share attributable to holders of ordinary shares - diluted was $0.83 compared to loss of $1.15 a year ago. The company continues to expect a net cash burn from operating activities of $7 to $12 million for 2014, and now expects to end the year with approximately $285 million in cash (mid-point). The estimated 2014 net cash burn from operating activities is primarily driven by an estimated net loss of $13 to $18 million, which includes an estimated $6 million of non-cash share-based compensation expense.

Prothena Corporation plc Announces Initiation of Multiple Ascending Dose Phase 1 Study of PRX002 in Patients with Parkinson's Disease

Prothena Corporation plc announced that the first patient with Parkinson's disease has been successfully dosed in a Phase 1 multiple ascending dose clinical trial of PRX002, a potential disease-modifying treatment for Parkinson's disease. This study builds upon an ongoing Phase 1 single ascending dose study initiated in April 2014 designed to evaluate PRX002 in healthy volunteers. This Phase 1 randomized, double-blind, placebo-controlled, multiple ascending dose study of PRX002 was initiated based upon safety and tolerability observed to date in the ongoing study in healthy volunteers, and is expected to enroll up to 60 patients with Parkinson's disease at multiple centers across the United States. The multiple ascending dose escalation trial is designed to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of PRX002, and will also evaluate multiple clinical and exploratory biomarkers. Patients will be enrolled in escalating dose cohorts of PRX002 or placebo and will be observed for up to 6 months. PRX002, a monoclonal antibody targeting -synuclein, has been tested in various cellular and animal models of synuclein-related disease. Passive immunization with 9E4, the murine version of PRX002, in multiple transgenic mouse models of Parkinson's disease reduced the appearance of synuclein pathology, protected synaptic connections and improved performance by the mice in behavioral testing. PRX002 may slow or reduce the progressive neurodegeneration associated with synuclein misfolding and/or the cell-to-cell transmission of the pathogenic forms of synuclein.

Prothena Corporation plc Presents at Wedbush 2014 Life Sciences Management Access Conference, Aug-12-2014 10:55 AM

Prothena Corporation plc Presents at Wedbush 2014 Life Sciences Management Access Conference, Aug-12-2014 10:55 AM. Venue: Le Parker Meridien, New York, New York, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
0PT:GR €17.01 EUR +0.111

0PT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 0PT.
View Industry Companies
 

Industry Analysis

0PT

Industry Average

Valuation 0PT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 10.5x
Price/Book 2.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 6.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PROTHENA CORP PLC, please visit www.prothena.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.